Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Envoy Medical (COCH) Raw Materials (2022 - 2025)

Envoy Medical's Raw Materials history spans 4 years, with the latest figure at $1.4 million for Q3 2025.

  • For Q3 2025, Raw Materials rose 1.18% year-over-year to $1.4 million; the TTM value through Sep 2025 reached $1.4 million, up 1.18%, while the annual FY2024 figure was $1.4 million, 19.28% up from the prior year.
  • Raw Materials for Q3 2025 was $1.4 million at Envoy Medical, down from $1.4 million in the prior quarter.
  • Across five years, Raw Materials topped out at $1.4 million in Q1 2025 and bottomed at $1.0 million in Q4 2022.
  • The 4-year median for Raw Materials is $1.4 million (2024), against an average of $1.3 million.
  • The largest annual shift saw Raw Materials increased 19.28% in 2024 before it grew 1.15% in 2025.
  • A 4-year view of Raw Materials shows it stood at $1.0 million in 2022, then increased by 15.05% to $1.2 million in 2023, then increased by 19.28% to $1.4 million in 2024, then fell by 0.87% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for COCH's Raw Materials are $1.4 million (Q3 2025), $1.4 million (Q2 2025), and $1.4 million (Q1 2025).